Investment in manufacturing and research facilities and development of facilities for new products
First written in FY2017. 18 of 31 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「The capital expenditure plan for the following consolidated fiscal year is ¥27 billion,」
Capital expenditure of ¥18,566 million was incurred in the current fiscal year, with ¥27,000 million planned for the following fiscal year. The plan focuses mainly on expanding manufacturing facilities, including ¥13,700 million for functional materials, ¥4,400 million for agricultural chemicals and ¥5,000 million for chemicals. - FY2026-H1RestatedAnnual report
「Net cash used in investing activities was ¥8.085 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥7.046 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and capital expenditures for the interim period totaled ¥8.085 billion. This was up from ¥7.046 billion in the same period of the previous year, but no specific milestones, such as the completion of new facilities, were disclosed. - FY2025AdvancedAnnual report
「The capital expenditure plan for the following consolidated fiscal year is ¥27 billion, broken down by segment as follows.」
The company made capital expenditures of ¥14.688 billion in the current fiscal year and plans capital expenditures of ¥21.5 billion in the following fiscal year. The plans include expanding manufacturing facilities across the Chemicals, Functional Materials, Agricultural Chemicals and Healthcare businesses. - FY2025-H1RestatedAnnual report
「Net cash used in investing activities was ¥7.046 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥8.486 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and net cash used in investing activities totaled ¥7.046 billion. No specific milestones, such as the completion of new facilities, were disclosed. - FY2024AdvancedAnnual report
「During the consolidated fiscal year, we made total capital expenditures of ¥23.204 billion on an acceptance basis. In the Functional Materials business, we made capital expenditures of ¥9.441 billion, mainly for the construction of semiconductor materials manufacturing facilities at NCK Co., Ltd., our South Korean subsidiary. In the Agricultural Chemicals business, we made capital expenditures of ¥6.831 billion, mainly for the construction of agrochemical active ingredient manufacturing facilities at the Onoda Plant.」
Capital expenditures totaled ¥23.204 billion, including the construction of semiconductor materials manufacturing facilities at NCK and agrochemical active ingredient manufacturing facilities at the Onoda Plant. - FY2024-Q3RestatedAnnual report
「Net cash used in investing activities was ¥11.92 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥13.47 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and net cash used in investing activities for the nine months totaled ¥11.92 billion. No new specific milestones, such as the completion of facilities, were disclosed. - FY2024-Q2RestatedAnnual report
「Net cash used in investing activities was ¥8.486 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥9.633 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and net cash used in investing activities for the six months totaled ¥8.486 billion. No specific milestones, such as the completion of new facilities, were disclosed. - FY2024-Q1RestatedAnnual report
「Net cash used in investing activities was ¥5.078 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥4.345 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and net cash used in investing activities during the first quarter exceeded the level of the same period of the previous year. No specific milestones, such as the completion of new facilities, were disclosed. - FY2023AdvancedAnnual report
「During the consolidated fiscal year, we made total capital expenditures of ¥20.272 billion, mainly in the Functional Materials business.」
Capital expenditures totaled ¥20.272 billion, including investments in semiconductor materials manufacturing facilities at the Toyama Plant, display materials manufacturing facilities at the Sodegaura Plant, and agrochemical manufacturing facilities in India. Plans were also outlined for new construction of a third plant in South Korea and research facilities. - FY2023-Q3RestatedAnnual report
「Net cash used in investing activities was ¥13.47 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥6.781 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and capital expenditures for the nine months totaled ¥13.47 billion. No specific milestones, such as the completion of new facilities, were disclosed. - FY2023-Q2RestatedAnnual report
「Net cash used in investing activities was ¥9.633 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥6.091 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and capital expenditures for the six months totaled ¥9.633 billion. No specific milestones, such as the completion of new facilities, were disclosed. - FY2023-Q1RestatedAnnual report
「Net cash used in investing activities was ¥4.345 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥3.291 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and capital expenditures in the first quarter totaled ¥4.345 billion. No new specific milestones, such as the completion of facilities, were disclosed. - FY2022AdvancedAnnual report
「During the consolidated fiscal year, we made total capital expenditures of ¥10.951 billion, mainly in the Functional Materials business. In the Functional Materials business, we made capital expenditures of ¥5.725 billion, mainly to expand semiconductor materials manufacturing facilities at the Toyama Plant and display materials manufacturing facilities at the Sodegaura Plant.」
The company expanded semiconductor materials and display materials manufacturing facilities in the Functional Materials business and invested a total of ¥10.951 billion. It also outlined plans to develop functional product research facilities at the Sodegaura Plant from November 2024 to October 2025. - FY2022-Q3RestatedAnnual report
「Net cash used in investing activities was ¥6.781 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥10.857 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued. Capital expenditures for the nine months were below the level of the same period of the previous year, but there was no change in the policy of continuing capital investment. - FY2022-Q2RestatedAnnual report
「Net cash used in investing activities was ¥6.091 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥2.585 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and capital expenditures for the six months totaled ¥6.091 billion. No specific milestones, such as the completion of new facilities, were disclosed. - FY2021AdvancedAnnual report
「During the consolidated fiscal year, we made total capital expenditures of ¥15.8 billion, mainly in the Chemicals and Pharmaceuticals businesses. In the Chemicals business, we made capital expenditures of ¥4.903 billion, mainly to expand cyanuric acid production facilities at the Toyama Plant.」
The company made total capital expenditures of ¥15.8 billion in fiscal 2020, including the expansion of cyanuric acid production facilities at the Toyama Plant. It also outlined plans to develop agrochemical production facilities at the Onoda Plant and functional product manufacturing facilities at the Sodegaura Plant from fiscal 2021 onward. - FY2021-Q3RestatedAnnual report
「Net cash used in investing activities was ¥10.857 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥12.914 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, but net cash used in investing activities decreased year on year. No specific milestones, such as the completion of new facilities, were disclosed. - FY2021-Q2RestatedAnnual report
「Net cash used in investing activities was ¥2.585 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥2.423 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and net cash used in investing activities for the six months totaled ¥2.585 billion. - FY2021-Q1RestatedAnnual report
「Net cash used in investing activities was ¥1.557 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥603 million used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and net cash used in investing activities during the first quarter totaled ¥1.557 billion. No specific milestones, such as the completion of new facilities, were disclosed. - FY2020-Q3RestatedAnnual report
「Net cash used in investing activities was ¥12.914 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥9.684 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and net cash used in investing activities for the nine months totaled ¥12.914 billion. No specific milestones, such as the completion of new facilities, were disclosed. - FY2020-Q2RestatedAnnual report
「Net cash used in investing activities was ¥2.423 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥5.966 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, but net cash used in investing activities was below the level of the same period of the previous year. No specific milestones, such as the completion of new facilities, were disclosed. - FY2020-Q1RestatedAnnual report
「Net cash used in investing activities was ¥603 million, mainly due to capital expenditures at plants and other facilities, compared with ¥3.993 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, but net cash used in investing activities during the quarter was below the level of the same period of the previous year. No specific milestones, such as the completion of new facilities, were disclosed. - FY2019-Q3RestatedAnnual report
「Net cash used in investing activities was ¥9.684 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥12.03 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued, and net cash used in investing activities for the nine months totaled ¥9.684 billion. No specific milestones, such as the completion of new facilities, were disclosed. - FY2019-Q1RestatedAnnual report
「Net cash used in investing activities was ¥3.993 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥4.353 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities continued in the first quarter, with net cash used in investing activities totaling ¥3.993 billion. No specific milestones, such as the completion of new facilities, were disclosed. - FY2018AdvancedAnnual report
「During the consolidated fiscal year, we made total capital expenditures of ¥13.694 billion, mainly in the Functional Materials business. In the Functional Materials business, we made capital expenditures of ¥7.209 billion, mainly for the construction of semiconductor materials evaluation facilities at the Toyama Plant and semiconductor materials manufacturing facilities at NCK Co., Ltd.」
The company invested ¥13.694 billion, mainly in the Functional Materials business, and installed new facilities at the Toyama Plant and NCK. It also outlined plans to develop research and development facilities at the Materials Science Research Institute from January 2019 to March 2020. - FY2018-Q3AdvancedAnnual report
「Net cash used in investing activities was ¥12.03 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥7.835 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities totaled ¥12.03 billion for the nine months, up from ¥7.835 billion in the same period of the previous year. - FY2018-Q2AdvancedAnnual report
「Net cash used in investing activities was ¥6.265 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥4.509 billion used in the same period of the previous year.」
Capital expenditures at plants and other facilities totaled ¥6.265 billion, up from ¥4.509 billion in the same period of the previous year. - FY2018-Q1AdvancedAnnual report
「Net cash used in investing activities was ¥4.353 billion, mainly due to capital expenditures at plants and other facilities, compared with ¥369 million used in the same period of the previous year.」
Capital expenditures at plants and other facilities totaled ¥4.353 billion in the first quarter, increasing from the same period of the previous year. - FY2017First statedAnnual report
「During the consolidated fiscal year, we made total capital expenditures of ¥14.299 billion, mainly in the Chemicals, Functional Materials and Agricultural Chemicals businesses.」
Investments were made in semiconductor materials development facilities at the Toyama Plant and agrochemical formulation and manufacturing facilities at the Saitama Plant. The company also described plans to install ¥1.4 billion of new-product development facilities at the Onoda Plant from July 2017 to July 2018 in the following fiscal year.